Journals / Astım Allerji İmmünoloji / 2018 / Cilt: 16 - Sayı: 1

Triptorelin Acetate-Related Anaphylaxis in a Child with Central Precocious Puberty: Case Report

Santral Puberte Prekoks Tanılı Bir Çocukta Triptorelin Asetat İlişkili Anafilaksi: Olgu Sunumu

Pages
63–65
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although the risk of anaphylaxis with this drug is low, the possibility should be considered and appropriate measures taken.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Anaphylaxis is an acute, potentially life-threatening allergic multisystemic hypersensitivity reaction.
📊
Key Findings & Data:Although the anaphylaxis incidence is not clearly known, serious reactions are seen at a rate of approximately 1-3 per 10,000.
💡
Conclusion & Impact:Although the risk of anaphylaxis with this drug is low, the possibility should be considered and appropriate measures taken.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Anaphylaxis is an acute, potentially life-threatening allergic multisystemic hypersensitivity reaction. Although the anaphylaxis incidence is not clearly known, serious reactions are seen at a rate of approximately 1-3 per 10,000. Drugs are among the most common causes of anaphylactic reactions. Triptorelin acetate treatment aims to alleviate the clinical symptoms of early pubertal development, the psychological consequences and the effects on growth. Triptorelin acetate is major long-acting gonadotropin releasing hormone (GnRH) analogue. Our case diagnosed with central precocious puberty was being followed up by the pediatric endocrinology department when anaphylaxis occurred following an injection at the 18th month of treatment. Anaphylaxis with Triptorelin acetate has been reported in only two cases in the literature. Although the risk of anaphylaxis with this drug is low, the possibility should be considered and appropriate measures taken.

Özet

Anafilaksi, ani gelişen, hayatı tehdit eden sistemik aşırı duyarlılık reaksiyonudur. Anafilaksi sıklığı net bilinmemekle beraber ciddi reaksiyonlar yaklaşık 1-3/10.000 sıklığında görülmektedir. Anafilaktik reaksiyonların en sık sebeplerinden biri ilaçlardır. Triptorelin asetat tedavisi ile puberte prekoks klinik belirtilerinin, psikolojik sonuçlarının ve hastalığın büyüme üzerindeki etkilerinin hafifletilmesi amaçlanmaktadır. Triptorelin asetat uzun etkili Gonodotropin Salgılatan Hormon (GnRH) analoğudur. Yazıda, santral puberte prekoks nedeni ile endokrinoloji tarafından takip edilmekteyken tedavisinin 18. ayındaki enjeksiyonu sonrası gelişen anafilaksi olgusu sunulmuştur. Literatürde Triptorelin asetat ile anafilaksi 2 olguda bildirilmiştir. Triptorelin asetat ile anafilaksi riski nadir olmasına rağmen, uygun önlemler alınmalı ve akılda tutulmalıdır.

🔖

Cite This Article

ŞİRİN, S. K., ASİLSOY, S., BÖBER, E., UZUNER, N., KARAMAN, Ö. (2018). Triptorelin Acetate-Related Anaphylaxis in a Child with Central Precocious Puberty: Case Report. Astım Allerji İmmünoloji, Cilt: 16 - Sayı: 1, 63–65. https://ajindex.com/articles/144431

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-6
  2. Neyzi O, Günöz H, Furman A, Bundak R, Gökçay G, Darendeliler F ve ark. Türk çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hastalıkları Dergisi 2008;51:1-14
  3. Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol 1995;132:699-704
  4. Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP. Variations in pituitarygonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology. Acta Paediatr 1994;83:627-33
  5. Tuvemo T, Gustafsson J, Proos LA; Swedish Growth Hormone Group. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Horm Res 2002;57:27-31
  6. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159:3-8
  7. Antoniazzi F, Zamboni G. Central precocious puberty: Current treatment options. Paediatr Drugs 2004;6:211-31
  8. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med 2008;358:2366-77
  9. Türk Toraks Derneği. Erişim tarihi: 5 Aralık 2015. www.toraks. org.tr/userfiles/file/Anafilaksi.pdf 10. Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab 2015;28:1387-9
  10. Lee JW, Kim HJ, Choe YM, Kang HS, Kim SK, Jun YH, et al. Significant adverse reactions to long-acting gonadotropinreleasing hormone agonists for the treatment of central precocious puberty and early onset puberty. Ann Pediatr Endocrinol Metab 2014;19:135-40
  11. Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics 2000;106:762-6.